Works matching IS 13520504 AND DT 2013 AND VI 20 AND IP 11

Results: 7

Role of hepatitis C virus substitutions and interleukin-28 B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 761, doi. 10.1111/jvh.12097
By:
- Liang, C.‐M.;
- Hu, T.‐H.;
- Lu, S.‐N.;
- Hung, C.‐H.;
- Huang, C.‐M.;
- Wang, J.‐H.;
- Yen, Y.‐H.;
- Chen, C.‐H.;
- Chang, K.‐C.;
- Tsai, M.‐C.;
- Kuo, Y.‐H.;
- Lee, C.‐M.
Publication type:
Article
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 745, doi. 10.1111/jvh.12173
By:
- Afdhal, N. H.;
- Zeuzem, S.;
- Schooley, R. T.;
- Thomas, D. L.;
- Ward, J. W.;
- Litwin, A. H.;
- Razavi, H.;
- Castera, L.;
- Poynard, T.;
- Muir, A.;
- Mehta, S. H.;
- Dee, L.;
- Graham, C.;
- Church, D. R.;
- Talal, A. H.;
- Sulkowski, M. S.;
- Jacobson, I. M.
Publication type:
Article
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 779, doi. 10.1111/jvh.12104
By:
- Bruijne, J.;
- Thomas, X. V.;
- Rebers, S. P.;
- Weegink, C. J.;
- Treitel, M. A.;
- Hughes, E.;
- Bergmann, J. F.;
- Knegt, R. J.;
- Janssen, H. L. A.;
- Reesink, H. W.;
- Molenkamp, R.;
- Schinkel, J.
Publication type:
Article
Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 811, doi. 10.1111/jvh.12115
By:
- Hou, J.‐L.;
- Jia, J.‐D.;
- Wei, L.;
- Zhao, W.;
- Wang, Y. M.;
- Cheng, M.;
- Tang, X.;
- Tan, D.‐M.;
- Ren, H.;
- Tang, H.;
- Cohen, D.;
- Llamoso, C.
Publication type:
Article
Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg- IFN and ribavirin treatment.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 770, doi. 10.1111/jvh.12099
By:
- Ackefors, M.;
- Nyström, J.;
- Wernerson, A.;
- Gjertsen, H.;
- Sönnerborg, A.;
- Weiland, O.
Publication type:
Article
Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBs Ag-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 801, doi. 10.1111/jvh.12102
By:
- Pande, C.;
- Sarin, S. K.;
- Patra, S.;
- Kumar, A.;
- Mishra, S.;
- Srivastava, S.;
- Bhutia, K.;
- Gupta, E.;
- Mukhopadhyay, C. K.;
- Dutta, A. K.;
- Trivedi, S. S.
Publication type:
Article
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 11, p. 790, doi. 10.1111/jvh.12106
By:
- Di Marco, V.;
- Covolo, L.;
- Calvaruso, V.;
- Levrero, M.;
- Puoti, M.;
- Suter, F.;
- Gaeta, G. B.;
- Ferrari, C.;
- Raimondo, G.;
- Fattovich, G.;
- Santantonio, T.;
- Alberti, A.;
- Bruno, R.;
- Mussini, C.;
- Mondelli, M.;
- Donato, F.;
- Craxì, A.
Publication type:
Article

Works matching IS 13520504 AND DT 2013 AND VI 20 AND IP 11

Role of hepatitis C virus substitutions and interleukin-28 B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.

Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China.

Evolution of fibrosis during HCV recurrence after liver transplantation - influence of IL-28B SNP and response to peg- IFN and ribavirin treatment.

Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBs Ag-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial.

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.